NCT03471884

Brief Summary

A novel nonintubated thoracoscopic technique is promising to enhance recovery after thoracic surgery. However, the effects of nonintubated technique on specific organ protection in not clear yet. In this randomized trial, the effect of nonintubated technique on lung function protection will be evaluated via PaO2/FiO2 ratio, oxidative stress and inflammatory cytokines serially in lung cancer patients undergoing thoracoscopic lobectomy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
82

participants targeted

Target at P50-P75 for not_applicable nonsmall-cell-lung-cancer

Timeline
Completed

Started Mar 2018

Shorter than P25 for not_applicable nonsmall-cell-lung-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2018

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

March 13, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 21, 2018

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

March 21, 2018

Status Verified

March 1, 2018

Enrollment Period

10 months

First QC Date

March 13, 2018

Last Update Submit

March 19, 2018

Conditions

Keywords

Thoracoscopic surgery,Airway Management,Anesthesia

Outcome Measures

Primary Outcomes (1)

  • Lung function assessment

    Lung function will be assessed by serial arterial blood gas analyses to obtain oxygenation index (PaO2/FiO2).

    12 hours

Secondary Outcomes (1)

  • Oxidative and systemic inflammatory cytokines.

    24 hours

Study Arms (2)

Nonintubated thoracoscopic lobectomy

EXPERIMENTAL

Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation

Procedure: Nonintubated thoracoscopic lobectomy

Intubated thoracoscopic lobectomy

ACTIVE COMPARATOR

Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation

Procedure: Intubated thoracoscopic lobectomy

Interventions

Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.

Nonintubated thoracoscopic lobectomy

Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.

Intubated thoracoscopic lobectomy

Eligibility Criteria

Age20 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adults (\> 20 year-old), lung cancer patients undergoing thoracoscopic lobectomy

You may not qualify if:

  • obesity (BMI \> 26 kg/m2)
  • previous ipsilateral thoracic surgery
  • severe ventilatory insufficiency (oxygen/BiPAP user)
  • poor cardiopulmonary function (preop forced expiratory volume at one second (FEV1) \<60%, preop left ventricular ejection fraction \< 50%)
  • autoimmune disease requiring chronic steroids
  • patients with difficult airway management, pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, 100, Taiwan

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungRespiratory Insufficiency

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesRespiration Disorders

Study Officials

  • Ming-Hui Hung, MD, MSc

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ming-Hui Hung, MD, MSc

CONTACT

Jin-Shing Chen, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 13, 2018

First Posted

March 21, 2018

Study Start

March 1, 2018

Primary Completion

December 31, 2018

Study Completion

December 31, 2018

Last Updated

March 21, 2018

Record last verified: 2018-03

Locations